Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug296 | Angiotensin-(1-7) Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045888 | Ganglion Cysts NIH | 1.00 |
| D013577 | Syndrome NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.
Description: Adverse events that can atleast unlikely be attributed to SGB
Measure: Adverse events related to SGB Time: 3 MonthsDescription: All adverse events related to COVID-19
Measure: All Adverse events Time: 3 MonthsDescription: Death due to any cause
Measure: Death Time: 3 MonthsDescription: Change from baseline clinical respiratory/pulmonary function as assessed by change in PF ratio
Measure: Assessment of respiratory/ pulmonary function Time: 3 MonthsDescription: Change from last imaging data obtained prior to SGB procedure
Measure: Radiographic criteria Time: 3 MonthsDescription: Change from baseline clinical cardiac function as assessed by improvement in arrhythmia as measured by standard of care ECG ( rate, rhythm and / or any aberrant electro physiological changes)
Measure: Cardiac function Time: 3 MonthsThis study will establish the safety and efficacy of using stellate ganglion blocks in patients with ARDS due to COVID-19 disease.
Description: Adverse events related to SGB.
Measure: Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS Time: 3 monthDescription: All adverse events.
Measure: Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS Time: 3 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports